Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Nasdaq-100 Stock Index / Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.</li>
<li>We are getting near-term cautious on Technology and semiconductors (XLK, SOXX), as the Nasdaq 100 (QQQ) and XLK display near-term bearish failed breakouts below $745 and $197, respectively.</li>
<li>These breaks are our signal to be neutral/cautious in the near-term, as it suggests a continuation of the 5-month consolidation and potential test of the June/July lows</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.
We are getting near-term cautious on Technology and semiconductors (XLK, SOXX), as the Nasdaq 100 (QQQ) and XLK display near-term bearish failed breakouts below $745 and $197, respectively.
These breaks are our signal to be neutral/cautious in the near-term, as it suggests a continuation of the 5-month consolidation and potential test of the June/July lows


False Breakout on QQQ and XLK?; Monitor Yesterday's Lows for Near-Term Direction

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Veeva Systems Inc Class A / Equity Bottom-Up

<ul><li>Veeva Systems has spent years building one of the most entrenched software franchises in life sciences, but its next phase could look considerably different from the business investors have known.</li><li>The company is simultaneously completing a major strategic separation from Salesforce, moving customers onto its proprietary Vault CRM platform, and developing AI agents designed to perform labor-intensive pharmaceutical work.</li><li>That combination could matter because Veeva already sits inside critical commercial, clinical, regulatory, safety, and data workflows used by pharmaceutical and biotechnology companies.</li></ul>

Veeva Systems has spent years building one of the most entrenched software franchises in life sciences, but its next phase could look considerably different from the business investors have known.The company is simultaneously completing a major strategic separation from Salesforce, moving customers onto its proprietary Vault CRM platform, and developing AI agents designed to perform labor-intensive pharmaceutical work.That combination could matter because Veeva already sits inside critical commercial, clinical, regulatory, safety, and data workflows used by pharmaceutical and biotechnology companies.

Veeva Systems Is Breaking Free From Salesforce—& AI Could Change Everything!

<ul><li>Veeva Systems reported its fiscal 2027 second quarter results with total revenue of $928 million, surpassing prior guidance, alongside non-GAAP operating income of $416 million.</li><li>The company indicated strong execution across key segments, highlighting record performance in its Commercial segment, driven by broad-based growth in CRM, content, data offerings, and particularly the Crossix business unit.</li><li>A significant strategic focus remains on artificial intelligence initiatives, notably the Veeva Falcon agentic labor platform.</li></ul>

Veeva Systems reported its fiscal 2027 second quarter results with total revenue of $928 million, surpassing prior guidance, alongside non-GAAP operating income of $416 million.The company indicated strong execution across key segments, highlighting record performance in its Commercial segment, driven by broad-based growth in CRM, content, data offerings, and particularly the Crossix business unit.A significant strategic focus remains on artificial intelligence initiatives, notably the Veeva Falcon agentic labor platform.

Veeva Systems Unlocks A New AI Model With Falcon Agentic Labor!

<ul><li>Veeva Systems has moved deeper into agentic AI for life sciences with its acquisition of Copli, an agentic medical, legal, and regulatory solutions provider that is now available as Veeva Falcon MLR.</li><li>The deal comes shortly after Veeva’s fiscal Q1 2027 earnings call, where management reported total quarterly revenue of $883 million and non-GAAP operating income of $395 million, while framing Falcon as a disruptive new layer of “agentic labor” across life sciences workflows.</li><li>Copli’s core appeal appears tied to one of pharma’s most persistent bottlenecks: MLR review, where promotional, medical, and regulatory content must be checked before reaching doctors and patients.</li></ul>

Veeva Systems has moved deeper into agentic AI for life sciences with its acquisition of Copli, an agentic medical, legal, and regulatory solutions provider that is now available as Veeva Falcon MLR.The deal comes shortly after Veeva’s fiscal Q1 2027 earnings call, where management reported total quarterly revenue of $883 million and non-GAAP operating income of $395 million, while framing Falcon as a disruptive new layer of “agentic labor” across life sciences workflows.Copli’s core appeal appears tied to one of pharma’s most persistent bottlenecks: MLR review, where promotional, medical, and regulatory content must be checked before reaching doctors and patients.

Veeva Systems' Latest Acquisition Pushes Agentic AI Deeper Into Pharma!

<ul><li>Veeva Systems reported a solid start to fiscal year 2027, surpassing guidance with total revenue of $883 million and non-GAAP operating income of $395 million for the first quarter.</li><li>The company highlighted strong execution across its business segments, emphasizing innovation particularly in life sciences artificial intelligence (AI) applications.</li><li>A significant focus was on Veeva Falcon, described as a disruptive innovation aimed at automating agentic labor within drug development.</li></ul>

Veeva Systems reported a solid start to fiscal year 2027, surpassing guidance with total revenue of $883 million and non-GAAP operating income of $395 million for the first quarter.The company highlighted strong execution across its business segments, emphasizing innovation particularly in life sciences artificial intelligence (AI) applications.A significant focus was on Veeva Falcon, described as a disruptive innovation aimed at automating agentic labor within drug development.

Veeva’s Ostro Deal: Can AI-Driven Q&A Supercharge Commercial Cloud?

United States

Veeva Systems Inc. provides cloud-based business services. The Company offers enterprise applications, multichannel platform, customer relationship, and content management solutions. Veeva Systems serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Veeva Systems Inc Class A (VEEV US)

False Breakout on QQQ and XLK?; Monitor Yesterday's Lows for Near-Term Direction

Pre-Market Report: Bearish False Breakouts on $QQQ and $XLK signal it is time to get near-term cautious as the 5-month consolidation continues....

Vermilion Research

Veeva Systems Is Breaking Free From Salesforce—& AI Could Change Everything!

Veeva Systems has spent years building one of the most entrenched software franchises in life sciences, but its next phase could look considerably...

Baptista Research

Veeva Systems Unlocks A New AI Model With Falcon Agentic Labor!

Veeva Systems reported its fiscal 2027 second quarter results with total revenue of $928 million, surpassing prior guidance, alongside non-GAAP...

Baptista Research

Veeva Systems' Latest Acquisition Pushes Agentic AI Deeper Into Pharma!

Veeva Systems has moved deeper into agentic AI for life sciences with its acquisition of Copli, an agentic medical, legal, and regulatory...

Baptista Research

Veeva’s Ostro Deal: Can AI-Driven Q&A Supercharge Commercial Cloud?

Veeva Systems reported a solid start to fiscal year 2027, surpassing guidance with total revenue of $883 million and non-GAAP operating income of...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)